Clinical Trial Update: A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs [Phase 3]

View source ↗

Summary

Phase 3 study comparing deucravacitinib to placebo in biologic disease-modifying anti-rheumatic drug-naïve patients with active psoriatic arthritis to evaluate …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Sotyktu (Deucravacitinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Psoriatic Arthritis | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-10-24